DV
Dividend Vision

GHRS — GH Research PLC

GH Research PLC (GHRS)

Total return is 53.2% over the past 5.1 years, 41.5 points behind SPY at 94.7%. Its deepest 1-year drawdown was 27.4%.

GHRS is an equity fund focused on GH Research PLC, a clinical-stage biopharmaceutical company. The fund does not currently distribute dividends and lacks a disclosed distribution yield or expense ratio, reflecting its structure as a single-stock holding rather than a diversified portfolio. This holding appeals primarily to investors seeking direct exposure to GH Research's business developments in psychedelic-assisted therapies rather than to income-focused dividend investors.

GHRS key facts

Asset type
Stock
Asset class
Equity
Inception date
06/25/2021
Last close
$29.49
Market cap
$1,969,762,048
Average volume
233800.0
Beta
1.29
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.91